<table>
<thead>
<tr>
<th>Score</th>
<th>Scientific Merit Rating Scale (Revised May 2014)</th>
<th>Priority for funding</th>
</tr>
</thead>
</table>
| 4.8 – 5.0 | - Exceptional research with extremely significant and novel aims  
- Leading edge nationally and internationally  
- Addresses extremely important questions, challenges existing paradigms and will substantially improve our understanding of cancer  
- Extremely likely that all objectives will be met  
- No weaknesses                                                                                                                                                                                                                                     | Highest              |
| 4.5 – 4.7 | - Outstanding research with very significant and novel aims  
- Nationally and internationally competitive  
- Addresses essential questions and will have a major impact on our understanding of cancer  
- Very likely that all objectives will be met  
- Virtually no weaknesses                                                                                                                                                                                                                        | Very High            |
| 4.2 – 4.4 | - Excellent research with significant and novel aims  
- Nationally competitive and potentially internationally relevant  
- Will have a significant impact on our current knowledge of cancer  
- Somewhat likely that all objectives will be met  
- At least one minor weakness                                                                                                                                                                                                                   | High                 |
| 3.9 – 4.1 | - Very good research with important and novel aims  
- Potentially nationally competitive  
- Potential to contribute considerably to our knowledge of cancer  
- Very good likelihood that most objectives will be met  
- Some minor weaknesses that can be addressed during the term of the grant                                                                                                                                                                      | Medium-High          |
| 3.6 – 3.8 | - Good research with important aims  
- Potentially nationally relevant  
- Potential to improve our knowledge of cancer  
- Good likelihood that most objectives will be met  
- At least one moderate weakness                                                                                                                                                                                                             | Medium-Low           |
| 3.3 – 3.5 | - Research with low potential to yield important results  
- Numerous moderate weakness                                                                                                                                                                                                                   | Low                  |
| 3.0 – 3.2 | - Research with very low potential to yield important results  
- At least one major weakness                                                                                                                                                                                                                   | Lowest               |
| Below 3.0 | - Research in need of further development before being competitive  
- Numerous major weaknesses                                                                                                                                                                                                                   | None                 |
| Unscored (mark as 0.01) | The application was triaged by the panel and not discussed. The weaknesses of the proposed research far outweigh the strengths and therefore there is a low expectation of success.                                                                                                                                  | None                 |